WCBA
CRL icon

Weaver C. Barksdale & Associates’s Charles River Laboratories CRL Stock Holding History

Weaver C. Barksdale & Associates’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$11K Buy
97
+5
+5% +$544 0.01% 261
2017
Q3 		$10K Sell
92
-6
-6% -$616 0.01% 270
2017
Q2 		$10K Sell
98
-19
-16% -$1.75K 0.01% 266
2017
Q1 		$11K Hold
117
– – 0.01% 257
2016
Q4 		$9K Buy
117
+28
+31% +$2.13K 0.01% 287
2016
Q3 		$7K Buy
89
+17
+24% +$1.43K 0.01% 319
2016
Q2 		$6K Hold
72
– – 0.01% 329
2016
Q1 		$5K Hold
72
– – ﹤0.01% 379
2015
Q4 		$6K Sell
72
-11
-13% -$793 ﹤0.01% 344
2015
Q3 		$5K Hold
83
– – ﹤0.01% 373
2015
Q2 		$6K Hold
83
– – ﹤0.01% 353
2015
Q1 		$7K Hold
83
– – 0.01% 332
2014
Q4 		$5K Sell
83
-7
-8% -$439 ﹤0.01% 372
2014
Q3 		$5K Sell
90
-5
-5% -$286 ﹤0.01% 361
2014
Q2 		$5K Buy
95
+13
+16% +$713 ﹤0.01% 378
2014
Q1 		$5K Sell
82
-18
-18% -$1.05K ﹤0.01% 373
2013
Q4 		$5K Hold
100
– – ﹤0.01% 376
2013
Q3 		$5K Sell
100
-9
-8% -$413 ﹤0.01% 371
2013
Q2 		$4K Buy
+109
New +$4.67K ﹤0.01% 400

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Weaver C. Barksdale & Associates's CRL Position: Q4 2017 in Review

Weaver C. Barksdale & Associates increased its Charles River Laboratories (CRL) stake by 5.4% in Q4 2017, buying an estimated $544 and bringing the position to 97 shares worth $11K. The position accounts for 0.01% of the portfolio, ranked #261.

Weaver C. Barksdale & Associates first reported a position in CRL in Q2 2013 and has held it in 19 quarters since. 339 funds tracked by Wall St. Rank hold CRL as of Q4 2017.

  • Weaver C. Barksdale & Associates held 97 shares of Charles River Laboratories worth $11K as of Q4 2017.
  • Weaver C. Barksdale & Associates bought 5 Charles River Laboratories shares in Q4 2017, an estimated $544.
  • Charles River Laboratories made up 0.01% of Weaver C. Barksdale & Associates's portfolio in Q4 2017, its #261 holding.
  • Weaver C. Barksdale & Associates first reported a position in Charles River Laboratories in Q2 2013 and has held it in 19 quarters since.
  • 339 funds tracked by Wall St. Rank held Charles River Laboratories as of Q4 2017.

Based on Weaver C. Barksdale & Associates's 13F filing for Q4 2017, filed 10 Jan 2018.